{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T18:07:57Z","timestamp":1773770877674,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2005,6]]},"DOI":"10.1007\/s11940-005-0010-6","type":"journal-article","created":{"date-parts":[[2007,6,5]],"date-time":"2007-06-05T18:57:22Z","timestamp":1181069842000},"page":"173-182","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["Neuromyelitis optica"],"prefix":"10.1007","volume":"7","author":[{"given":"Dean M.","family":"Wingerchuk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian G.","family":"Weinshenker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"10_CR1","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","volume":"53","author":"DM Wingerchuk","year":"1999","unstructured":"Wingerchuk DM, Hogancamp WF, O\u2019Brien PC, Weinsh-enker BG: The clinical course of neuromyelitis optica (Devic\u2019s syndrome). Neurology 1999, 53:1107\u20131114. This is the largest contemporary longitudinal series of patients with NMO.","journal-title":"Neurology"},{"key":"10_CR2","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1055\/s-2002-36534","volume":"22","author":"BA Cree","year":"2002","unstructured":"Cree BA, Goodin DS, Hauser SL: Neuromyelitis optica. Semin Neurol 2002, 22:105\u2013122.","journal-title":"Semin Neurol"},{"key":"10_CR3","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1002\/ana.410340211","volume":"34","author":"RN Mandler","year":"1993","unstructured":"Mandler RN, Davis LE, Jeffery DR, Kornfeld M: Devic\u2019s neuromyelitis optica: a clinicopathological study of 8 patients. Ann Neurol 1993, 34:162\u2013168.","journal-title":"Ann Neurol"},{"key":"10_CR4","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1136\/jnnp.60.4.382","volume":"60","author":"JI O\u2019Riordan","year":"1996","unstructured":"O\u2019Riordan JI, Gallagher HL, Thompson AJ, et al.: Clinical, CSF, and MRI findings in Devic\u2019s neuro-myelitis optica. J Neurol Neurosurg Psychiatry 1996, 60:382\u2013387.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10_CR5","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/S0140-6736(03)12784-5","volume":"361","author":"BG Weinshenker","year":"2003","unstructured":"Weinshenker BG: Neuromyelitis optica: what it is and what it might be. Lancet 2003, 361:889\u2013890.","journal-title":"Lancet"},{"key":"10_CR6","doi-asserted-by":"publisher","first-page":"834","DOI":"10.2741\/1267","volume":"9","author":"DM Wingerchuk","year":"2004","unstructured":"Wingerchuk DM: Neuromyelitis optica: current concepts. Front Biosci 2004, 9:834\u2013840.","journal-title":"Front Biosci"},{"key":"10_CR7","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","volume":"364","author":"VA Lennon","year":"2004","unstructured":"Lennon VA, Wingerchuk DM, Kryzer TJ, et al.: A serum autoantibody marker of neuromyelitis optica: distinc-tion from multiple sclerosis. Lancet 2004, 364:2106\u20132112. The first report of a serum biomarker, NMO-IgG, for CNS demyelinating diseases. The marker seems highly specific for NMO and suggests that NMO and the Japanese opticospinal form of MS are the same disorder.","journal-title":"Lancet"},{"key":"10_CR8","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1474-4422(03)00308-9","volume":"2","author":"J Kira","year":"2003","unstructured":"Kira J: Multiple sclerosis in the Japanese population. Lancet Neurology 2003, 2:117\u2013127. This is an excellent review.","journal-title":"Lancet Neurology"},{"key":"10_CR9","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1093\/brain\/awf151","volume":"125","author":"CF Lucchinetti","year":"2002","unstructured":"Lucchinetti CF, Mandler RN, McGavern D, et al.: A role for humoral mechanisms in the pathogenesis of Devic\u2019s neuromyelitis optica. Brain 2002, 125:1450\u20131461. This modern, detailed immunopathologic study has added substantial weight to the argument that NMO is a humorally mediated disorder.","journal-title":"Brain"},{"key":"10_CR10","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1212\/01.WNL.0000049912.02954.2C","volume":"60","author":"DM Wingerchuk","year":"2003","unstructured":"Wingerchuk DM, Weinshenker BG: Neuromyelitis optica: Clinical predictors of a relapsing course and survival. Neurology 2003, 60:848\u2013853.","journal-title":"Neurology"},{"key":"10_CR11","volume-title":"Cochrane Library","author":"G Filippini","year":"2004","unstructured":"Filippini G, Brusaferri F, Sibley WA, et al.: Corticoster-oids or ACTH for acute exacerbations in multiple sclerosis. In Cochrane Library. Oxford; Wiley Inter-Science. 2004, Issue 4."},{"key":"10_CR12","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1056\/NEJM199202273260901","volume":"326","author":"RW Beck","year":"1992","unstructured":"Beck RW, Cleary PA, Anderson Jr MM, et al.: A random-ized, controlled trial of corticosteroids in the treat-ment of acute optic neuritis. N Engl J Med 1992, 326:581\u2013588.","journal-title":"N Engl J Med"},{"key":"10_CR13","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1001\/archopht.1997.01100160715008","volume":"115","author":"The Optic Neuritis Study Group","year":"1997","unstructured":"The Optic Neuritis Study Group: Visual function 5 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol 1997, 115:1545\u20131552.","journal-title":"Arch Ophthalmol"},{"key":"10_CR14","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s004150070172","volume":"247","author":"F Brusaferri","year":"2000","unstructured":"Brusaferri F, Candelise L: Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials. J Neurol 2000, 247:435\u2013442.","journal-title":"J Neurol"},{"key":"10_CR15","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1002\/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q","volume":"46","author":"BG Weinshenker","year":"1999","unstructured":"Weinshenker BG, O\u2019Brien PC, Petterson TM, et al.: A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999, 46:878\u2013886. This is the first randomized controlled study of an interven-tion for corticosteroid-refractory exacerbations of demyelinat-ing disease.","journal-title":"Ann Neurol"},{"key":"10_CR16","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1212\/01.WNL.0000138437.99046.6B","volume":"63","author":"K Ruprecht","year":"2004","unstructured":"Ruprecht K, Klinker E, Dintelmann T, et al.: Plasma exchange for severe optic neuritis: Treatment of 10 pat i ent s. Neurology 2004, 63:1081\u20131083. This case series suggests that plasma exchange also may bene-fit refractory optic neuritis.","journal-title":"Neurology"},{"key":"10_CR17","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1001\/jama.269.16.2110","volume":"269","author":"GA Chrousos","year":"1993","unstructured":"Chrousos GA, Kattah JC, Beck RW, et al.: Side effects of glucocorticoid treatment: experience of the optic neuritis Treatment Trial. JAMA 1993, 269:2110\u20132112.","journal-title":"JAMA"},{"key":"10_CR18","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1212\/WNL.51.4.1219","volume":"51","author":"RN Mandler","year":"1998","unstructured":"Mandler RN, Ahmed W, Dencoff JE: Devic\u2019s neuro-myelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology 1998, 51:1219\u20131220. This was the first case series to show NMO stability with immunosuppressive therapy.","journal-title":"Neurology"},{"key":"10_CR19","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/S0140-6736(04)16808-6","volume":"364","author":"G Remuzzi","year":"2004","unstructured":"Remuzzi G, Lesti M, Gotti E, et al.: Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial. Lancet 2004, 364:503\u2013512.","journal-title":"Lancet"},{"key":"10_CR20","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1002\/art.10947","volume":"48","author":"GJ Silverman","year":"2003","unstructured":"Silverman GJ, Weisman S: Rituximab therapy and autoimmune disorders. Prospects for anti-B cell therapy. Arthritis Rheum 2003, 48:1484\u20131492.","journal-title":"Arthritis Rheum"},{"issue":"Suppl 5","key":"10_CR21","first-page":"A492","volume":"62","author":"B Cree","year":"2004","unstructured":"Cree B, Lamb S, Chin A, et al.: Tolerability and effects of rituximab (anti-CD20 antibody) in neuromyelitis optica (NMO) and rapidly worsening multiple sclerosis (MS). Neurology 2004, 62(Suppl 5):A492. This abstract describes initial favorable experience with rituximab.","journal-title":"Neurology"},{"key":"10_CR22","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1017\/S0317167100053932","volume":"31","author":"J Bakker","year":"2004","unstructured":"Bakker J, Metz L: Devic\u2019s neuromyelitis optica treated with intravenous gamma globulin (IVIG). Can J Neurol Sci 2004, 31:265\u2013267.","journal-title":"Can J Neurol Sci"},{"key":"10_CR23","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1016\/S0140-6736(02)12023-X","volume":"360","author":"HP Hartung","year":"2002","unstructured":"Hartung HP, Gonsette R, Konig N, et al.: Mitoxantrone in progressive multiple sclerosis: a placebo-con-trolled, double-blind, randomized, multicenter trial. Lancet 2002, 360:2018\u20132025.","journal-title":"Lancet"},{"key":"10_CR24","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1212\/01.WNL.0000095425.84407.39","volume":"61","author":"DS Goodin","year":"2003","unstructured":"Goodin DS, Arnason BG, Coyle PK, et al.: The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: Report of the Therapeutic and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2003, 61:1332\u20131338.","journal-title":"Neurology"},{"issue":"Suppl 8","key":"10_CR25","first-page":"S58","volume":"56","author":"B Weinstock-Guttman","year":"2004","unstructured":"Weinstock-Guttman B, Feichter J, Lincoff N, Bakshi R: Mitoxantrone (Novantrone) for treatment of relapsing neuromyelitis optica. Ann Neurol 2004, 56(Suppl 8):S58. Additional evaluation of mitoxantrone, now approved for severe MS, may be warranted but is not a B cell-specific therapy.","journal-title":"Ann Neurol"},{"key":"10_CR26","doi-asserted-by":"crossref","unstructured":"Minagar A, Sheremata WA: Treatment of Devic\u2019s disease with methotrexate and prednisone. Intl J MS Care (Serial online) 2000, 2(4).","DOI":"10.7224\/1537-2073-2.4.43"},{"key":"10_CR27","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s00415-003-0979-2","volume":"250","author":"R Bergamaschi","year":"2003","unstructured":"Bergamaschi R, Uggetti C, Tonietti S, et al.: A case of relapsing neuromyelitis optica treated with glatiramer acetate. J Neurol 2003, 250:359\u2013361.","journal-title":"J Neurol"},{"key":"10_CR28","first-page":"487","volume":"48","author":"Y Itoyama","year":"2000","unstructured":"Itoyama Y, Saida T, Tashiro K, et al.: Japanese multi-center, randomized, double-blind trial of interferon beta-1b in relapsing-remitting multiple sclerosis: two year results. Ann Neurol 2000, 48:487. The final results of this study are needed to determine the effects of interferon therapy on the Japanese opticospinal form of MS.","journal-title":"Ann Neurol"},{"key":"10_CR29","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1212\/WNL.58.1.143","volume":"58","author":"M Keegan","year":"2001","unstructured":"Keegan M, Pineda AA, McClelland RL, et al.: Plasma exchange for severe attacks of demyelination: predictors of response. Neurology 2001, 58:143\u2013146.","journal-title":"Neurology"},{"key":"10_CR30","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1212\/WNL.55.8.1135","volume":"55","author":"JH Noseworthy","year":"2000","unstructured":"Noseworthy JH, O\u2019Brien PC, Weinshenker BG, et al.: IV immunoglobulin does not reverse established weakness in MS. Neurology 2000, 55:1135\u20131143.","journal-title":"Neurology"},{"key":"10_CR31","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1212\/WNL.56.11.1514","volume":"56","author":"JH Noseworthy","year":"2001","unstructured":"Noseworthy JH, O\u2019Brien PC, Petterson TM, et al.: A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology 2001, 56:1514\u20131522.","journal-title":"Neurology"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-005-0010-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11940-005-0010-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-005-0010-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-005-0010-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T11:53:58Z","timestamp":1659095638000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11940-005-0010-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["10"],"URL":"https:\/\/doi.org\/10.1007\/s11940-005-0010-6","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,6]]},"assertion":[{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}